Financial Outlook: Building Durable Growth and Long–Term Value

Protalix enters 2026 with a profitable commercial business through its partnerships and a focused pipeline aligned to areas of high unmet need. The Company has a strong balance sheet, with no outstanding debt or warrants. The Company believes that its current business model limits downside risk while preserving significant upside potential as the Company progresses its clinical programs, expands its commercial footprint, and pursues strategic partnerships to accelerate impact and scale.

Priorities remain consistent:

  1. Support our commercial partnerships
  2. Advance PRX–115 as a potential best–in–class therapy for uncontrolled gout
  3. Advance rare renal programs leveraging the Company's R&D strengths

Based on current estimates, management expects: 

  • Total revenue in 2026 to range from approximately $78.0 million to $83.0 million including the $25.0 million milestone which the Company is entitled to from Chiesi.
    • Full–year 2026 revenues from sales of Elfabrio without milestones to range from approximately $33.0 million to $35.0 million.
    • Full–year 2026 revenues from sales of Elelyso to range from approximately $20.0 million to $23.0 million.